Breaking News Instant updates and real-time market news.

XRAY

Dentsply Sirona

$60.75

0.24 (0.40%)

, PDCO

Patterson Companies

$39.05

-0.21 (-0.53%)

08:14
11/28/16
11/28
08:14
11/28/16
08:14

Credit Suisse to hold meetings and booth tours

Dental & Animal Health Meeting & Booth Tours will be held in New York on November 28.

XRAY

Dentsply Sirona

$60.75

0.24 (0.40%)

PDCO

Patterson Companies

$39.05

-0.21 (-0.53%)

DHR

Danaher

$79.56

0.4 (0.51%)

ZTS

Zoetis

PAHC

Phibro Animal Health

$28.00

-0.05 (-0.18%)

WOOF

VCA Inc.

$64.58

0.24 (0.37%)

  • 28

    Nov

  • 29

    Nov

  • 15

    Dec

XRAY Dentsply Sirona
$60.75

0.24 (0.40%)

09/22/16
09/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Packaging Corp. (PKG) initiated with a Sell at Goldman. 2. Netlist (NLST) initiated with a Buy at B. Riley. 3. Weyerhaeuser (WY) initiated with a Conviction Buy at Goldman. 4. bluebird bio (BLUE) reinstated with a Buy at Roth Capital. 5. Dentsply Sirona (XRAY) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/16
MSCO
11/01/16
UPGRADE
MSCO
Overweight
Dentsply Sirona upgraded to Overweight from Equal Weight at Morgan Stanley
11/01/16
11/01/16
UPGRADE
Target $69

Overweight
Dentsply Sirona upgraded on growth, valuation at Morgan Stanley
As previously reported, Morgan Stanley upgraded Denstply Sirona to Overweight from Equal Weight and raised its price target to $69 from $65. Analyst Steve Beuchaw said Densply's relative valuation weakness positions the company for better performance despite negative dental market sentiment. He expects Dentsply's organic growth to accelerate in 2017 driven by digital dentistry adoption, a focus on commercial headcount, easing digital equipment comps, and revenue synergies. Beauchaw expects the company's double digit free cash flow growth potential to improve investor sentiment.
11/22/16
PIPR
11/22/16
NO CHANGE
PIPR
Patterson cancellation a positive for Dentsply, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes Patterson Companies (PDCO) cancelling its exclusive selling agreement with legacy Sirona products beyond September 2017 as positive for Dentsply Sirona (XRAY). The move is unsurprising given the changing industry dynamics, O'Brien tells investors in a research note. He points out that the initial exclusive agreement was established in 1998. Assuming Henry Schein (HSIC) starts selling legacy Sirona equipment, the cancellation is a positive for Dentsply as this will ultimately allow the company to increase cross-selling opportunities with those customers, O'Brien argues. He's been calling for a cancellation of the exclusive selling agreement with Patterson saying Dentsply has been adamant about realizing sales synergies through increased cross-selling opportunities. The analyst reiterates an Overweight rating on Dentsply with a $70 price target. Patterson in pre-market trading is down 17% to $39.20 after reporting a decline in North American dental consumables sales of 2.5%. Dentsply shares are down 2% to $58.40.
PDCO Patterson Companies
$39.05

-0.21 (-0.53%)

11/23/16
JPMS
11/23/16
NO CHANGE
Target $40
JPMS
Neutral
Patterson Companies price target lowered to $40 from $48 at JPMorgan
JPMorgan analyst Lisa Gill lowered her price target for Patterson Companies to $40 from $48 after the company reported Q2 earnings below her estimate and cut its FY17 earnings guidance. The analyst remains cautious on Patterson's outlook "given the lack of visibility into the timing of improvement on both sides of the business." She keeps a Neutral rating on the shares.
11/01/16
NRCS
11/01/16
NO CHANGE
NRCS
Amazon.com should partner with Patterson Companies, says Northcoast
Northcoast said Amazon.com (AMZN) has a strong interest in entering the dental market and has spent time and resources attempting to build relationships with manufacturers and distributors to gain product procurement, which so far has been unsuccessful. The firm's analyst said Patterson (PDCO) is aggressively trying to reinvent how dental distribution will occur in the future and is building a new IT backbone, making huge investments in technical service. Northcoast said Patterson is on a path to disrupt the industry and could accelerate this effort with a partnership with Amazon. The firm continues to view Patterson as undervalued, with out without Amazon, and recommends investors build positions at this time.
11/21/16
BARD
11/21/16
NO CHANGE
BARD
Outperform
Baird expects Amazon.com distribution announcement with Patterson
Following industry conversions, Baird analyst Jeff Johnson expects Patterson Companies (PDCO) to announce an Amazon.com (AMZN) distribution agreement tomorrow. What the analyst hadnt considered and is now hearing is that Amazon could fulfill orders placed through Patterson's order portal, lowering Patterson's fulfillment costs and given the company breathing room as it pursues DSO deals. Johnson rates Patterson a Neutral with a $48 price target.
DHR Danaher
$79.56

0.4 (0.51%)

11/15/16
BOFA
11/15/16
NO CHANGE
Target $93
BOFA
Buy
Danaher added to US 1 List at BofA/Merrill
BofA/Merrill analyst Derik de Bruin added Danaher to the US 1 List saying the company is one of the better positioned Life Sciences sector companies following the US election outcome. The analyst believes Danaher's end markets exposure to Water infrastructure spending, Dental and Product ID businesses, and increased aerospace and defense stand to benefit from the Republican sweep. Further, de Bruin said the Cepheid acquisition is a good strategic fit with its leading molecular diagnostics platform. The analyst reiterates his Buy rating and raised his price target to $93 from $89 on Danaher shares.
11/11/16
COWN
11/11/16
UPGRADE
Target $95
COWN
Outperform
Danaher upgraded to Outperform from Market Perform at Cowen
Cowen analyst Doug Schenkel upgraded Danaher to Outperform and raised his price target to $95 from $85. The analyst believes recent M&A will drive core revenue growth to 5% by 2020, and provides margin expansion opportunities, and recent downward revisions to consensu estimates makes 2016-2018 estimates beatable.
09/07/16
BERN
09/07/16
NO CHANGE
BERN
Danaher acquisition should be positive over the mid to long-term, says Bernstein
After Danaher (DHR) agreed to buy Cepheid (CPHD), Bernstein analyst Steven Winoker says that the deal was expensive. However, the analyst says that Cepheid has high recurring revenue, fast growth, and strong synergies with Danaher. Winoker thinks that the deal leaves Danaher well-positioned for growth over the medium to longer term. He keeps a $92 price target and Outperform rating on the stock.
10/12/16
EVER
10/12/16
NO CHANGE
Target $89
EVER
Buy
Danaher acquisition of Phenomenex highly attractive, says Evercore ISI
Evercore ISI analyst Ross Muken is not surprised by Danaher's (DHR) acquisition of Phenomenex saying it is one of the "great consumable assets that remained in Life Science Tools." Muken said the deal terms are "remarkably attractive" and estimates Danaher paid more than $700M for Phenomenex He said revenues are close to $200M, implying an EV/EBITDA multiple in the low to mid-teens, and ROIC north of 10% by year 5, and imply year 1 accretion of 3-5c, and 10-15c by year 5. Muken rates Danaher a Buy with an $89 price target on shares.
ZTS Zoetis

10/11/16
STFL
10/11/16
NO CHANGE
STFL
Zoetis outlook positive despite cattle headwinds, says Stifel
Stifel analyst Jonathan Block says that Zoetis is facing a number of headwinds in cattle, including difficult comps and unfavorable cattle and milk prices. However, he thinks the company will be boosted in Q4 and into fiscal 2017 by easing comps and its "competitive" vaccine offering. Block says that the outlook for the company's companion animal and swine offerings remain positive, and he thinks the company's EPS can beat expectations over the next 12-24 months. Block keeps a Buy rating on the shares.
09/29/16
BOFA
09/29/16
INITIATION
Target $60
BOFA
Buy
Zoetis reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin restated coverage on Zoetis with a Buy and a $60 price target.
07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
AbbVie remains Jefferies' Top Pick in Global Pharma
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his firm's Top Pick in Global Pharmaceuticals, followed by Eli Lilly (LLY), Novartis (NVS), GlaxoSmithKline (GSK) and Zoetis (ZTS). The analyst this morning upgraded GSK to Buy from Hold. Holford also remains positive on Roche (RHHBY), Abbott (ABT) and Pfizer (PFE). The analyst's least preferred names are Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Merck (MRK). The Q2 earnings season offers "few clear beat and raise" stories and looks weakest for AstraZeneca (AZN) against preliminary consensus, Holford tells investors in a pre-earnings research note.
09/07/16
FBCO
09/07/16
NO CHANGE
FBCO
Progressive, U.S. Silica and Zoetis added to US Focus List at Credit Suisse
Credit Suisse added Progressive (PGR), U.S. Silica (SLCA) and Zoetis (ZTS) to the US Focus List and removed Allison Transmission (ALSN) from the US Focus List and Sealed Air (SEE) from the US Focus List and Global Focus List
PAHC Phibro Animal Health
$28.00

-0.05 (-0.18%)

04/19/16
MACQ
04/19/16
NO CHANGE
Target $23
MACQ
Neutral
Phibro Animal Health price target lowered to $23 from $31 at Macquarie
Macquarie analyst Matthew Brooks lowered his price target for Phibro Animal Health to $23 saying the potential Mecadox approval withdrawal highlights the risks to company's Medicated Feed Additives business. The analyst thinks the MFA business should trade on a lower target valuation multiple. He keeps a Neutral rating on Phibro.
11/10/16
GABE
11/10/16
DOWNGRADE
GABE
Hold
Phibro Animal Health downgraded to Hold from Buy at Gabelli
Gabelli analyst Kevin Kdera downgraded Phibro Animal Health to Hold following in-line Q1 results due to valuation.
11/11/16
MACQ
11/11/16
DOWNGRADE
MACQ
Underperform
Phibro Animal Health downgraded to Underperform from Neutral at Macquarie
11/11/16
MACQ
11/11/16
DOWNGRADE
Target $21
MACQ
Underperform
Phibro Animal Health downgraded to Underperform on MFA slowdown at Macquarie
As previously reported, Macquarie downgraded Phibro Animal Health to Underperform from Neutral and reduced its price target to $21. Analyst Matthew Brooks saying valuation is too high given the structurally challenged MFA business.
WOOF VCA Inc.
$64.58

0.24 (0.37%)

10/24/16
BNCH
10/24/16
INITIATION
Target $90
BNCH
Buy
VCA Inc. initiated with a Buy at Benchmark
Benchmark analyst Raymond Myers initiated VCA Inc with a Buy and a $90 price target.
02/04/16
FBCO
02/04/16
INITIATION
Target $63
FBCO
Outperform
VCA Inc. initiated with an Outperform at Credit Suisse
Credit Suisse analyst Erin Wilson initiated VCA Inc with an Outperform rating and a $63 price target.
09/29/16
BOFA
09/29/16
INITIATION
Target $78
BOFA
VCA Inc. reinstated with a with a Buy at BofA/Merrill
BofA/Merrill analyst Derik De Bruin reinstated VCA Inc. with a Buy and a $78 price target.
02/04/16
02/04/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AT&T (T) initiated with a Buy at DA Davidson... Abaxis (ABAX) initiated with an Underperform at Credit Suisse... Aratana Therapeutics (PETX) initiated with an Outperform at Credit Suisse... Care.com (CRCM) initiated with an Equal Weight at Morgan Stanley... GCP Applied Technologies (GCP) initiated with a Buy at Jefferies... Heritage-Crystal Clean (HCCI) initiated with a Buy at Roth Capital... IDEXX (IDXX) initiated with an Outperform at Credit Suisse... Nexvet Biopharma (NVET) initiated with an Outperform at Credit Suisse... PetMed Express (PETS) initiated with an Underperform at Credit Suisse... Phibro Animal Health (PAHC) initiated with an Outperform at Credit Suisse... Pure Storage (PSTG) initiated with a Perform at Oppenheimer... SeaWorld (SEAS) initiated with a Neutral at Janney Capital... Seattle Genetics (SGEN) initiated with an Overweight at Barclays... VCA Inc. (WOOF) initiated with an Outperform at Credit Suisse... Verizon (VZ) initiated with a Neutral at DA Davidson... Zoetis (ZTS) initiated with an Outperform at Credit Suisse.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$17.93

-0.1 (-0.55%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Periodicals
Early Twitter investor Sacca would 'love' to see the company sold, CNBC reports »

One of the earliest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.